10-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

Amendment No.1

þ	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the fiscal year ended December 31, 2014

OR

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from __________   to _________

Commission file number 000-00935

MEDITE CANCER DIAGNOSTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	36-4296006
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)
4203 SW 34th Street, Orlando, FL	32811
(Address of principal executive offices)	(Zip Code)

(407) 996-9630

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Name of each exchange on which registered
None	Not Applicable

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, $0.001 par value

(Title of class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes ¨ No þ

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.       Yes ¨   No þ

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ    No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes þ    No ¨

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.   See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer   ¨	Accelerated filer   ¨
Non-accelerated filer ¨	Smaller reporting company þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨   No þ

The aggregate market value of the common stock held by non-affiliates of the Company was $9,145,062, based upon the closing price of shares of the Company’s common stock, $0.001 par value per share, of $3.00 as reported on the OTC Bulletin Board on December 31, 2014, the last day of the Company’s most recently completed second fiscal quarter. Shares of common stock held by each current executive officer and director and by each person who is known by the Company to own 5% or more of the outstanding common stock have been excluded from this computation in that such persons may be deemed to be affiliates of the Company. This determination of affiliate status is not a conclusive determination for other purposes.

The number of shares of common stock outstanding as of May 07, 2015 was 19,664,781

DOCUMENTS INCORPORATED BY REFERENCE

None.

Explanatory Note

This Amendment No. 1 on Form 10-K /A (“Amendment No. 1”) is an amendment to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 (the “Report”). This Amendment No. 1 is being filed solely to add the XBRL (eXtensible Business Reporting Language) information in Exhibit 101 that was excluded from the Report. This Amendment No. 1 makes no other change to the Report as filed with the Securities and Exchange Commission on May 8, 2015.

Exhibit 101 provides the following items for the fiscal year ended December 31, 2014, formatted in XBRL: (i) the Condensed Balance Sheets for the fiscal years ended December 31, 2013 and 2014, (ii) the Condensed Statements of Operations for the fiscal years ended December 31, 2013 and 2014, (iii) the Condensed Statements of Cash Flows for the fiscal years ended December 31, 2013 and 2014 and (iv) the Notes to Condensed Financial Statements for the fiscal years ended December 31, 2013 and 2014.

PART II — OTHER INFORMATION

ITEM 15. EXHIBITS

101.INS XBRL Instance Document

101.SCH XBRL Taxonomy Extension Schema Document

101.CAL XBRL Taxonomy Calculation Linkbase Document

101.DEF XBRL Taxonomy Definition Linkbase Document

101.LAB XBRL Taxonomy Label Linkbase Document

101.PRE XBRL Taxonomy Presentation Linkbase Document

SIGNATURES

                Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MEDITE Cancer Diagnostics, Inc.
By:	/s/ Michaela Ott
	Michaela Ott
	Chief Executive Officer Principal Executive Officer
Date:	May 11, 2015

By:	/s/ Robert McCullough, Jr.
	Robert McCullough, Jr.
	Chief Financial Officer Principal Financial Officer
Date:   May 11, 2015

                Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Michaela Ott	Chief Executive Officer	May 11, 2015
Michaela Ott	(Principal Executive Officer)
	and Director
/s/ Michael Ott	Chief Operating Officer and	May 11, 2015
Michael Ott	Director
/s/ Robert McCullough, Jr.	Chief Financial Officer	May 11, 2015
Robert McCullough, Jr.	(Principal Financial Officer) and
	Director
/s/ Alexander M. Milley	Director	May 11, 2015
Alexander M. Milley
/s/ John Abeles, M.D.	Director	May 11, 2015
John Abeles, M.D.
/s/ Augusto Ocana	Director	May 11, 2015
Augusto Ocana

XML

Bank Debts and Lines of Credit (Detail1) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014
2015	$ 189
2016	1,074
2017	68
2018	67
2019	0
Total	$ 1,398

XML

Income Taxes (Significant Components Of The Company's Deferred Tax Assets And Liabilities) (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Deferred Tax Assets:
Net Operating Loss Carryforwards	$ 24,500	$ 129
Accounts receivable timing differences	115	156
Property, plant and equipment	93
Total Deferred Tax Assets	24,708	285
Deferred Tax Liabilities:
Inventory Adjustment	0	(16)
Other	(39)	0
Total Deferred Tax Liabilities	(39)	(16)
Net Deferred Tax Asset	24,669	269
Valuation Allowance	(24,500)	0
Net Deferred Tax Asset	$ 169	$ 269

XML

Stockholders' Equity (Deficit) - Additional Information (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Stock Issued During Period, Value, New Issues	$ 1,979
Proceeds from Issuance of Common Stock	$ 1,979	$ 0
Officers and Directors [Member]
Equity Method Investment Ownership Number Of Shares Held	16,661,615
Equity Method Investment, Ownership Percentage	86.00%
Warrants and Stock Options [Member]
Anti-dilutive securities not included in the computation of diluted loss per share	142,308	39
Preferred Stock [Member]
Anti-dilutive securities not included in the computation of diluted loss per share	4,991	4,738
Restricted Stock [Member]
Stock Issued During Period, Shares, New Issues	1,237,125
Share Price	$ 1.60

XML

Income Taxes (Company's Gross Unrecognized Tax Benefits) (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014
Gross Unrecognized tax benefits at December 31, 2013	$ 0
Increases in tax positions for current year	0
Settlements	0
Lapse in statute of limitations	0
Gross Unrecognized tax benefits at December 31, 2014	$ 0

XML

Summary of Preferred Stock Terms (Parenthetical) (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Series A Convertible Preferred Stock [Member]
Preferred stock, liquidation Value per share	$ 4.50
Series B Convertible Preferred Stock [Member]
Preferred stock, liquidation Value per share	$ 4.00
Preferred stock, frequency of dividend payment	Quarterly
Preferred stock, dividend date of commencement	Mar. 31, 2001
Series C Convertible Preferred Stock [Member]
Preferred stock, liquidation Value per share	$ 3.00
Preferred stock, frequency of dividend payment	Quarterly
Preferred stock, dividend date of commencement	Mar. 31, 2002
Series D Convertible Preferred Stock [Member]
Preferred stock, liquidation Value per share	$ 1,000
Preferred stock, frequency of dividend payment	Quarterly
Preferred stock, dividend date of commencement	Apr. 30, 2002
Series E Convertible Preferred Stock [Member]
Preferred stock, liquidation Value per share	$ 22.00
Preferred stock, frequency of dividend payment	Quarterly
Preferred stock, dividend date of commencement	May 31, 2002

XML

Summary of Significant Accounting Policies (Detail)	12 Months Ended
	Dec. 31, 2014
Building [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	33 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Computer Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Computer Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Office furniture and equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Office furniture and equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	2 years

XML

Commitments and Contingencies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Line Items]
Loss Contingency, Damages Paid, Value	$ 86,000
Agreed To Legal Settlement	$ 15,000
Loss Contingency, Settlement Agreement, Court	As part of the decision from the local court, which the Company is appealing, the Company could be subject to a penalty up to a maximum of $304,000 if in the future it is found by the court to have improperly infringed on the product design of Hologic Deutchland GmbH

XML

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2014

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

The following is a summary of the components of property and equipment as of (in thousands):

	December 31,		December 31,
	2014		2013
Land	$	233	$	244
Buildings		1,291		1,352
Machinery and equipment		529		407
Office furniture and equipment		265		240
Vehicles		103		39
Computer equipment		110		86
Construction in progress		559		386
Less: Accumulated depreciation		(999)		(887)
	$	2,091	$	1,867

XML

Leases-Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Operating Leases, Rent Expense	$ 157,136
Operating Leases, Rent Expense, Sublease Rentals	3,816
Monthly Lease	4,270
Minimum [Member]
Operating Leases, Rent Expense	2,345
Maximum [Member]
Operating Leases, Rent Expense	$ 2,563

XML

Reconciliation of Numerator and Denominator Used in Calculation of Loss Per Share (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Basic and Diluted:
Reported net loss (in thousands)	$ (699)	$ 54
Less unpaid and undeclared preferred stock dividends	109	0
Net loss applicable to common stockholder	$ (808)	$ 54
Weighted average common shares outstanding	18,116,000	14,687,500
Net income (loss) per common share	$ (0.04)	$ 0.00

XML

Property and Equipment (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Land	$ 233	$ 244
Buildings	1,291	1,352
Machinery and equipment	529	407
Office furniture and equipment	265	240
Vehicles	103	39
Computer equipment	110	86
Construction in progress	559	386
Less: Accumulated depreciation	(999)	(887)
Total	$ 2,091	$ 1,867

XML

Income Taxes (Provision For Deferred Income Taxes) (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Current	$ 152	$ 51
Deferred	80	(33)
Total Income Tax Expense	$ 104	$ 19

XML

Stockholders' Equity (Warrants And Options Issued Outside Of The Plan For Employee Compensation) (Detail) (Warrants and Stock Options [Member], USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014
Options and Warrants, Opening Balance	0
Options and Warrants, Granted	0
Options and Warrants, Exercised	0
Options and Warrants, Expired	0
Options and Warrants, Ending Balance	0	0
Weighted Average Exercise Price, Opening Balance	$ 0
Weighted Average Exercise Price, Granted	$ 0
Weighted Average Exercise Price, Exercised	$ 0
Weighted Average Exercise Price, Expired	$ 0
Weighted Average Exercise Price, Ending Balance	$ 0	$ 0
Aggregate Intrinsic Value, Opening Balance	$ 0
Aggregate Intrinsic Value, Granted	0
Aggregate Intrinsic Value, Exercised	0
Aggregate Intrinsic Value, Expired	0
Aggregate Intrinsic Value, Ending Balance	0	0
Weighted Average Remaining Contractual Life(Years),Outstanding	0 years	0 years
Warrants Outstanding Granted Weighted Average Remaining Contractual Term	0 years
Warrants Outstanding Exercised Weighted Average Remaining Contractual Term	0 years
Warrants Outstanding Expired Weighted Average Remaining Contractual Term	0 years
Result of Merger [Member]
Options and Warrants, Opening Balance			62,140
Options and Warrants, Granted			81,298
Options and Warrants, Expired			(130)
Options and Warrants, Ending Balance	62,140		143,308
Weighted Average Exercise Price, Opening Balance			$ 4.00
Weighted Average Exercise Price, Granted			$ 1.60
Weighted Average Exercise Price, Expired			$ 4.00
Weighted Average Exercise Price, Ending Balance	$ 4.00		$ 2.64
Aggregate Intrinsic Value, Opening Balance			0
Aggregate Intrinsic Value, Granted			0
Aggregate Intrinsic Value, Expired			0
Aggregate Intrinsic Value, Ending Balance	$ 0		$ 0
Weighted Average Remaining Contractual Life(Years),Outstanding	9 years		6 years 5 months 16 days
Warrants Outstanding Granted Weighted Average Remaining Contractual Term			4 years 6 months
Warrants Outstanding Expired Weighted Average Remaining Contractual Term			0 years

XML

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

 Principle of Consolidation, Basis of Presentation and Significant Estimates

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.

In preparing the accompanying financial statements, management has made certain estimates and assumptions that affect reported amounts in the financial statements and disclosures of contingencies. Significant assumptions are required in the valuation of the allowance for doubtful accounts and inventory, valuation of intangible assets acquired in the reverse merger and deferred tax asset valuations. Changes in facts and circumstances may result in revised estimates and actual results may differ from these estimates.

Revenue Recognition  

The Company derives its revenue primarily from the sale of medical products and supplies for the diagnosis and prevention of cancer. Product revenue is recognized when all four of the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products has occurred; (3) the selling price of the product is fixed or determinable; and (4) collectability is reasonably assured. The Company generates the majority of its revenue from the sale of inventory. The Company recognizes revenue when title and risk of loss transfer to the customer and all other revenue recognition criteria have been met. For a small subset of sales, the Company and its customers agree in the sales contract that risk of loss and title transfer upon the Company packing the items for shipment, segregating the items packaged and notifying the Customer that their items are ready for pickup. The Company records such sales at time of completed packaging and segregation of the items from general inventory and notification has been confirmed by the customer.

Cash and Cash Equivalents

 The Company considers all cash on deposit and highly-liquid debt instruments purchased with original maturities of three months or less to be cash and cash equivalents.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation and amortization. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets as follows:

Buildings	33 yrs
Machinery and equipment	3-10yrs
Office furniture and equipment	2-10 yrs
Vehicles	5 yrs
Computer equipment	3-5 yrs

Normal maintenance and repairs for equipment are charged to expense as incurred, while significant improvements are capitalized.

Research and Development

All research and development costs are expensed as incurred. Research and development costs consist of engineering, product development, testing, developing and validating the manufacturing process, and regulatory related costs.

Acquired In-Process Research and Development

Acquired in-process research and development (“IPR&D”) that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, Medite will make a determination as to the then useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company tests IPR&D for impairment at least annually, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the IPR&D intangible asset is less than its carrying amount. If the Company concludes it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the IPR&D intangible asset with its carrying value is performed. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.

Impairment or Disposal of Long-Lived Assets Including Finite Lived Intangibles

At each balance sheet date or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, management of the Company evaluates the recoverability of such assets. An impairment loss is recognized if the amount of undiscounted cash flows is less than the carrying amount of the asset, in which case the asset is written down to fair value. The fair value of the asset is measured by either quoted market prices or the present value of estimated expected future cash flows using a discount rate commensurate with the risks involved. Unless events or circumstances have changed significantly, we generally do not re-test at year end assets acquired from a business combination in the year of acquisition.

Impairment of Indefinite Lived Intangible Assets Other Than Goodwill

The Company has the option first to assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, the Company concludes that it is not more likely than not that the indefinite-lived intangible asset is impaired, then the entity is not required to take further action. However, if the Company concludes otherwise, then it is required to determine the fair value of the indefinite-lived intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying amount in accordance with Financial Accounting Standards Board Codification Subtopic 350-30.

Goodwill

We allocate goodwill to reporting units based on the reporting unit expected to benefit from the business combination. We evaluate our reporting units on an annual basis. Goodwill is tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis (December 31 for us) and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit. Unless events or circumstances have changed significantly, we generally do not re-test at year end assets acquired from a business combination in the year of acquisition.

Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The fair value of each reporting unit is estimated using a discounted cash flow methodology. This analysis requires significant judgments, including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for our business, estimation of the useful life over which cash flows will occur, and determination of our weighted average cost of capital.

The estimates used to calculate the fair value of a reporting unit change from year to year based on operating results, market conditions, and other factors. Changes in these estimates and assumptions could materially affect the determination of fair value and goodwill impairment for each reporting unit.

Stock Based Compensation

We follow the guidance of FASB ASC 718-10, which requires that share-based payments be reflected as an expense based upon the grant-date fair value of those awards.   The expense is recognized over the remaining vesting periods of the awards, if any.  

Fair Value of Financial Instruments

The carrying value of accounts receivable, accounts payable, accrued expenses and notes payable approximate their respective fair values due to their short maturities.

Net Loss Per Share

Basic loss per share is calculated based on the weighted-average number of outstanding common shares. Diluted loss per share is calculated based on the weighted-average number of outstanding common shares plus the effect of dilutive potential common shares, using the treasury stock method. MEDITE’s calculation of diluted net loss per share excludes potential common shares as of December 31, 2014 and 2013 as the effect would be anti-dilutive (i.e. would reduce the loss per share).

 In accordance with SEC Accounting Series Release 280, the Company computes its income or loss applicable to common stock holders by subtracting dividends on preferred stock, including undeclared or unpaid dividends if cumulative, from it reported net loss and reports the same on the face of its statement of operations.

Income Taxes  

Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of currently due plus deferred taxes. Deferred tax assets and liabilities are determined based on differences between financial reporting carrying amounts and the respective tax bases of assets and liabilities, and are measured using tax rates and laws that are expected to be in effect when the differences are expected to be recovered or settled. Valuation allowances are provided against deferred tax assets if it is more likely than not that the deferred tax assets will not be realized.

The Company follows the guidance of FASB ASC 740-10 which relates to the Accounting for Uncertainty in Income Taxes, which seeks to reduce the diversity in practice associated with the accounting and reporting for uncertainty in income tax positions. This Interpretation prescribes a comprehensive model for financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns.

Legal Fees Associated with Loss Contingencies

It is the Company’s policy to estimate and accrue for its potential legal fees at the time of loss when it incurs a loss contingency that will require the services of legal professionals. Changes over time to the estimate of total legal fees to be incurred are expensed at the time of the change in estimate.

Recasting of Certain Prior Period Information

During 2014, we changed our reporting to show depreciation and amortization as its own line item within our statement of operations and comprehensive income. We have updated the results from 2013 to reflect these changes in 2014.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board issued amended accounting guidance on revenue recognition that will be applied to all contracts with customers. The objective of the new guidance is to improve comparability of revenue recognition practices across entities and to provide more useful information to users of financial statements through improved disclosure requirements. This guidance is effective for annual and interim periods beginning in 2017. Early adoption is not permitted. The Company is currently assessing the impact of adoption on its consolidated financial statements.

XML

Summary of Preferred Stock (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock Shares Issued	373,355	373,355
Dividends, Preferred Stock, Stock	$ 109,500	$ 0
Preferred Stock, Shares Outstanding	373,355	373,355
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized	590,197	590,197
Preferred Stock Shares Issued	47,250	47,250
Dividends, Preferred Stock, Stock	0	0
Preferred Stock, Shares Outstanding	47,250	47,250
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized	1,500,000	1,500,000
Preferred Stock Shares Issued	93,750	93,750
Dividends, Preferred Stock, Stock	28,125	0
Preferred Stock, Shares Outstanding	93,750	93,750
Series C Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized	1,666,666	1,666,666
Preferred Stock Shares Issued	38,333	38,333
Dividends, Preferred Stock, Stock	8,625	0
Preferred Stock, Shares Outstanding	38,333	38,333
Series D Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized	300,000	300,000
Preferred Stock Shares Issued	175,000	175,000
Dividends, Preferred Stock, Stock	41,250	0
Preferred Stock, Shares Outstanding	175,000	175,000
Series E Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized	800,000	800,000
Preferred Stock Shares Issued	19,022	19,022
Dividends, Preferred Stock, Stock	31,500	0
Preferred Stock, Shares Outstanding	19,022	19,022
Undesignated Preferred Series [Member]
Preferred Stock, Shares Authorized	5,143,137	5,143,137
Preferred Stock Shares Issued	0	0
Dividends, Preferred Stock, Stock	$ 0	$ 0
Preferred Stock, Shares Outstanding	0	0

XML

Leases (Tables)

12 Months Ended

Dec. 31, 2014

Leases [Abstract]

Schedule of Future Minimum Lease Payments for Capital Leases

Future minimum annual lease obligations under these leases as of December 31, 2014 are:

	Operating
Year	Leases
	(in thousands)
2015	$	112
2016		72
2017		33
2018		18
2019
Total	$	235

XML

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2014

Equity [Abstract]

Schedule of Earnings (loss) Per Share

A reconciliation of the numerator and the denominator used in the calculation of earnings (loss) per share is as follows:

	For the Years Ended December 31,
	2014		2013
Basic and Diluted:
Reported net loss (in thousands)	$	(699)	$	54
Less unpaid and undeclared preferred stock dividends		(109)		-
Net loss applicable to common stockholder	$	(808)	$	54
Weighted average common shares outstanding		18,116,000		14,687,500
Net income (loss) per common share	$	(0.04)	$	0.00

Summary of Company's Preferred Stock

A summary of the Company’s preferred stock as of December 31 is as follows. All calculations reflect the post-split calculations of 1 share for every 100 common shares which became effective March 2015 for all common stock and common stock equivalents.

			Shares Issued &				Preferred Stock Dividends
	Shares		Outstanding				Undeclared and Unpaid
Offering	Authorized		2014		2013		2014		2013
Series A convertible		590,197		47,250		47,250		—		—
Series B convertible, 10% cumulative		1,500,000		93,750		93,750		28,125		—
Series C convertible, 10% cumulative		1,666,666		38,333		38,333		8,625		—
Series D convertible, 10% cumulative		300,000		175,000		175,000		41,250		—
Series E convertible, 10% cumulative		800,000		19,022		19,022		31,500		—
Undesignated Preferred Series		5,143,137		—		—		—		—
Total Preferred Stock		10,000,000		373,355		373,355		109,500		—

Summary of Preferred Stock Terms

Summary of Preferred Stock Terms

Series A Convertible Preferred Stock

Liquidation Value:	$4.50 per share, $212,625
Conversion Price:	$10,303 per share
Conversion Rate:	0.00044—Liquidation Value divided by Conversion Price ($4.50/$10,303)
Voting Rights:	None
Dividends:	None
Conversion Period:	Any time

Series B Convertible Preferred Stock

Liquidation Value:	$4.00 per share, $375,000
Conversion Price:	$1,000 per share
Conversion Rate:	0.0040—Liquidation Value divided by Conversion Price ($4.00/$1,000)
Voting Rights:	None
Dividends:	10%—Quarterly—Commencing March 31, 2001
Conversion Period:	Any time

Cumulative dividends in arrears at December 31, 2014 were $520,665

Series C Convertible Preferred Stock

Liquidation Value:	$3.00 per share, $115,000
Conversion Price:	$600 per share
Conversion Rate:	0.0050—Liquidation Value divided by Conversion Price ($3.00/$600)
Voting Rights:	None
Dividends:	10%—Quarterly—Commencing March 31, 2002
Conversion Period:	Any time

Cumulative dividends in arrears at December 31, 2014 were $151,413

Series D Convertible Preferred Stock 

Liquidation Value:	$1,000 per share, $ 525,000
Conversion Price:	$1,000 per share
Conversion Rate:	.01—Liquidation Value divided by Conversion Price ($10.00/$1,000)
Voting Rights:	None
Dividends:	10%—Quarterly—Commencing April 30, 2002
Conversion Period:	Any time

Cumulative dividends in arrears at December 31, 2014 were $ 660,000

Series E Convertible Preferred Stock

Liquidation Value:	$22.00 per share, $418,488
Conversion Price:	$800.00 per share
Conversion Rate:	.0275—Liquidation Value divided by Conversion Price ($22.00/$800)
Voting Rights:	Equal in all respects to holders of common shares
Dividends:	10%—Quarterly—Commencing May 31, 2002
Conversion Period:	Any time

Cumulative dividends in arrears at December 31, 2014 were $558,173

Schedule of Stockholders' Equity Note, Warrants or Rights

Warrants outstanding

							Weighted
			Weighted				Average
			Average		Aggregate		Remaining
	Options and		Exercise		Intrinsic		Contractual
	Warrants		Price		Value		Life (Years)
Outstanding at December 31, 2012		—	$	—		—		—
Granted		—	$	—		—		—
Exercised		—		—		—		—
Expired		—		—		—		—
Outstanding at December 31, 2013		—	$	—		—		—
Outstanding as result of the merger		62,140		4.00		—		9.00
Granted		81,298		1.60		—		4.50
Expired		(130)		4.00		—		—
Outstanding at December 31. 2014		143,308	$	2.64		—		6.46

XML

Income Taxes-Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	$ 70,000,000
Deferred Tax Assets, Net of Valuation Allowance	169,000	269,000
Increase (Decrease) in Income Taxes	129,000
Loss In Net Operating Loss Carry Forwards	3,000,000	3,000,000
Minimum Percentage Of Change In Ownership	50.00%	50.00%
Operating Losses Carryforwards Expiration Date	2018
Percentage Of Income Tax Realized Upon Ultimate Settlement	50.00%
US subsidiary [Member]
Deferred Tax Assets, Net of Valuation Allowance		$ 129,000

XML

Summary of Preferred Stock (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Series B Convertible Preferred Stock [Member]
Convertible preferred stock, cumulative dividend rate	10.00%	10.00%
Series C Convertible Preferred Stock [Member]
Convertible preferred stock, cumulative dividend rate	10.00%	10.00%
Series D Convertible Preferred Stock [Member]
Convertible preferred stock, cumulative dividend rate	10.00%	10.00%
Series E Convertible Preferred Stock [Member]
Convertible preferred stock, cumulative dividend rate	10.00%	10.00%

XML

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Federal Income Tax Note

The provision for income taxes consists of the following for the years ended December 31 (in thousands).  

	2014		2013
Federal	$	129	$	19
State and local		—		—
Foreign		(25)		—
Total income tax expense	$	104	$	19

	2014		2013
Current		152		51
Deferred		(48)		(32)
Total Income Tax Expense		104		19

Federal Statutory Rate To Income Before Taxes

For the years ended December 31, 2014 and 2013, the provision for income taxes differs from the expected tax provision computed by applying the U.S. federal statutory rate to income before taxes as a result of the following:

	2014			2013
Statutory U.S. federal rate		(35.0)	%		25.0	%
Permanent differences		—			—
Change in estimate of German tax rates		(10)	%		—
Application of valuation allowance to US deferred tax assets upon merger		18	%		—
Other		—			—
Valuation allowance		44.0	%		—	%
Provision for income tax expense(benefit)		17	%		25	%

Schedule of Deferred Tax Assets and Liabilities

The significant components of the Company’s deferred tax assets and liabilities are as follows:

	2014		2013
	(in thousands)
Deferred Tax Assets:
Net Operating Loss Carryforwards	$	24,500		129
Accounts receivable timing differences		115		156
Property, plant and equipment		93
Total Deferred Tax Assets		24,708		285
Deferred Tax Liabilities:
Inventory Adjustment		-		(16)
Other		(39)		-
Total Deferred Tax Liabilities		(39)		(16)
Net Deferred Tax Asset		24,669		269
Valuation Allowance		(24,500)		-
Net Deferred Tax Asset	$	169		269

Schedule of Unrecognized Tax Benefits Roll Forward

The following table summarizes the activity related to the Company’s gross unrecognized tax benefits (in thousands):

	Amount
Gross Unrecognized tax benefits at December 31, 2013	$	—
Increases in tax positions for current year		—
Settlements		—
Lapse in statute of limitations		—
Gross Unrecognized tax benefits at December 31, 2014	$	—

XML

Segment Information (Tables)

12 Months Ended

Dec. 31, 2014

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

The Company operates in one operating segment. However, the Company has assets and operations in the United States and Germany. The following table shows the breakdown of our operations and assets by Country (in thousands):

	United States				Germany				Poland
	2014		2013		2014		2013		2014		2013
Total Assets	$	9,387	$	811	$	6,989	$	7,359	$	63	$	-
Property & equipment, net		98		17		1,985		1,850		8		-
Intangible Assets		8,315		2		58		63		4		-
Revenues		1,349		673		9,633		9,285		1		-
Net income (loss)		(730)		(20)		76		74		(45)		-

XML

The Company and Basis of Presentation

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

The Company and Basis of Presentation

Note 1. The Company and Basis of Presentation

MEDITE Cancer Diagnostics, Inc. (“MDIT”, “MEDITE” or the “Company”) was incorporated in Delaware in December 1998.

These statements include the accounts of MEDITE Cancer Diagnostics, Inc. (former CytoCore, Inc., the “Company”, “we” and “us”) and its wholly owned subsidiaries, which consists of MEDITE Enterprise, Inc., MEDITE GmbH, Burgdorf, Germany, MEDITE GmbH, Salzburg, Austria, MEDITE Lab Solutions Inc. (formerly MEDITE Inc.), Orlando, USA, MEDITE sp. z o.o., Zilona-Gora, Poland and CytoGlobe, GmbH, Burgdorf, Germany.

In April 2014, in a transaction more fully described in Footnote 3, the shareholders of the Company consummated a transaction in which 100% of the issued and outstanding shares of MEDITE Enterprise, Inc. were acquired by CytoCore, Inc. in exchange for the issuance by CytoCore, Inc. of 14,687,500 shares of its common stock to the shareholders of the Company. The result of this transaction was for the Company and its wholly owned subsidiaries to become wholly owned subsidiaries of CytoCore, Inc., a US public company. In addition, the shareholders of the Company became the majority owners of CytoCore, Inc., which resulted in the transaction being accounted for as a reverse merger, in which the financial statements of MEDITE Enterprise, Inc. and its subsidiaries became those of CytoCore, Inc., now MEDITE Cancer Diagnostics, Inc.          

MEDITE is a medical technology company specializing in the development, engineering, manufacturing and marketing of premium medical devices and consumables for detection, risk assessment and diagnosis of cancer and related diseases. By acquiring MEDITE the company changed from solely research operations to an operating company with 76 employees in three countries, a distribution network to about 70 countries worldwide, a well-known and established brand name, a wide range of selling products and the established infrastructure necessary for a company acting in the medical industry.

XML

The Company and Basis of Presentation - Additional Information (Detail)	Apr. 30, 2014
Medite Enterprise [Member]
Organization And Nature Of Operations [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	100.00%
Common Stock, Shares, Outstanding	14,687,500
Common Stock, Shares, Issued	14,687,500

XML

Bank Debts and Lines of Credit - Additional Information (Detail)	12 Months Ended					12 Months Ended		1 Months Ended		12 Months Ended					1 Months Ended
	Dec. 31, 2014 Chief Executive Officer And Chairman [Member] USD ($)	Dec. 31, 2014 Participation Rights Agreement In March 2009 [Member] EUR (€)	Dec. 31, 2014 Participation Rights Agreement In March 2009 [Member] Tranche One [Member] EUR (€)	Dec. 31, 2014 Participation Rights Agreement In March 2009 [Member] Tranche Two [Member] EUR (€)	Dec. 31, 2014 Medite GmbH, Burgdorf [Member] Unused lines of Credit [Member] EUR (€)	Dec. 31, 2014 Medite GmbH, Burgdorf [Member] Hannoversech Volksbank Credit lines 1 Issued in July 2006 [Member]	Dec. 31, 2012 Medite GmbH, Burgdorf [Member] Hannoversech Volksbank Credit lines 1 Issued in July 2006 [Member] EUR (€)	Mar. 31, 2015 Medite GmbH, Burgdorf [Member] Hannoversech Volksbank Credit lines 1 Issued in July 2006 [Member] Subsequent Event [Member] EUR (€)	Jan. 31, 2015 Medite GmbH, Burgdorf [Member] Hannoversech Volksbank Credit lines 1 Issued in July 2006 [Member] Subsequent Event [Member] EUR (€)	Dec. 31, 2014 Medite GmbH, Burgdorf [Member] Hannoversech Volksbank term loan 1 Issued in December 2006 [Member] EUR (€)	Dec. 31, 2014 Medite GmbH, Burgdorf [Member] Hannoversech Volksbank term loan 2 Issued in June 2006 [Member] EUR (€)	Dec. 31, 2014 Medite GmbH, Burgdorf [Member] Hannoversech Volksbank term loan 3 Issued in November 2008 [Member] EUR (€)	Dec. 31, 2014 CytoGlobe, GmbH, Burgdorf [Member] Hannoversech Volksbank Credit line 3 Issued in June 2012 [Member] EUR (€)	Dec. 31, 2014 Ventana Medical Systems, Inc [Member] USD ($)	Feb. 23, 2015 Ventana Medical Systems, Inc [Member] Subsequent Event [Member] USD ($)
Line of Credit Facility [Line Items]
Debt instrument face amount		€ 1,500,000	€ 750,000	€ 750,000						€ 500,000	€ 400,000	€ 400,000
Debt Instrument, Interest Rate, Stated Percentage		12.15%				3.77%				3.40%	3.60%	4.70%	3.77%
Debt instrument maturity period										September 2016	June 2016	December 31, 2018
Principal repayments										27,780	22,220	13,890
Interest expense, related party	1,700
Repayments of Related Party Debt	10,000
Line of Credit Facility, Maximum Borrowing Capacity							1,800,000		1,600,000				400,000
Line of Credit Facility, Increase (Decrease), Net								500,000
Line of Credit Facility, Interest Rate During Period						8.00%							8.00%
Line of Credit, Current					150,000
Notes Payable, Current														21,000
Repayments of Debt															38,281
Dividends Payable, Current															656,250
Due To Related Parties Current	121,700
Agreed To Convert Of Preferred Stock For Common Stock															$ 1,750,000
Number Of Stock To Be Converted From Preferred Stock															12,000

XML

Income Taxes (Provision For Income Taxes Differs From The Expected Tax Provision) (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Statutory U.S. federal rate	(35.00%)	25.00%
Permanent differences	0.00%	0.00%
Change in estimate of German tax rates	(10.00%)	0.00%
Application of valuation allowance to US deferred tax assets upon merger	18.00%	0.00%
Other	0.00%	0.00%
Valuation allowance	44.00%	0.00%
Provision for income tax expense(benefit)	17.00%	25.00%

XML

CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current Assets:
Cash	$ 230	$ 75
Accounts receivable, net of allowance for doubtful accounts	1,991	1,594
Inventories	3,415	3,953
Prepaid expenses and other current assets	154	487
Total current assets	5,790	6,109
Property and equipment, net	2,091	1,867
In-process Research and Development	4,620
Trademarks, trade names	1,240
Goodwill	2,453	0
Other Assets	245	194
Total assets	16,439	8,170
Current Liabilities:
Secured lines of credit and current portion of long-term debt	2,555	2,739
Account payable and accrued expenses	4,134	1,236
Advance - Related Parties	110	0
Total current liabilities	6,799	3,975
Long term debt, net of current portion	1,209	1,571
Total Liabilities	8,008	5,546
Commitments and Contingencies
Stockholders' Equity :
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 373,355 shares issued and outstanding as of December 31, 2014 (liquidation value of all classes of preferred stock $2,871 as of December 31, 2014)	1,487	0
Common stock, $0.001 par value; 3.5 billion shares authorized, 19,427,331 and 14,687,500 issued, issuable and outstanding as of December 31, 2014 and 2013 respectively	19	15
Additional paid-in capital	5,763	(15)
Treasury Stock	(327)	0
Accumulated other comprehensive income (loss)	(149)	287
Retained Earnings	1,638	2,337
Total stockholders' equity	8,431	2,624
Total liabilities and stockholders' equity	$ 16,439	$ 8,170

XML

Summary of Preferred Stock Terms (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Preferred Stock, Liquidation Value	$ 2,871,000
Series A Convertible Preferred Stock [Member]
Preferred Stock, Liquidation Value	212,625
Preferred Stock, Conversion Price	$ 10,303
Preferred Stock, Conversion Rate	0.00044%
Preferred Stock, Voting Rights	None
Preferred Stock, Dividends	0.00%
Preferred Stock, Conversion Period	Any time
Series B Convertible Preferred Stock [Member]
Preferred Stock, Liquidation Value	375,000
Preferred Stock, Conversion Price	$ 1,000
Preferred Stock, Conversion Rate	0.004%
Preferred Stock, Voting Rights	None
Preferred Stock, Dividends	10.00%	10.00%
Preferred Stock, Conversion Period	Any time
Preferred Stock, Cumulative and undeclared dividends in arrears	520,665
Series C Convertible Preferred Stock [Member]
Preferred Stock, Liquidation Value	115,000
Preferred Stock, Conversion Price	$ 600
Preferred Stock, Conversion Rate	0.005%
Preferred Stock, Voting Rights	None
Preferred Stock, Dividends	10.00%	10.00%
Preferred Stock, Conversion Period	Any time
Preferred Stock, Cumulative and undeclared dividends in arrears	151,413
Series D Convertible Preferred Stock [Member]
Preferred Stock, Liquidation Value	525,000
Preferred Stock, Conversion Price	$ 1,000
Preferred Stock, Conversion Rate	0.01%
Preferred Stock, Voting Rights	None
Preferred Stock, Dividends	10.00%	10.00%
Preferred Stock, Conversion Period	Any time
Preferred Stock, Cumulative and undeclared dividends in arrears	660,000
Series E Convertible Preferred Stock [Member]
Preferred Stock, Liquidation Value	418,488
Preferred Stock, Conversion Price	$ 800.00
Preferred Stock, Conversion Rate	0.0275%
Preferred Stock, Voting Rights	Equal in all respects to holders of common shares
Preferred Stock, Dividends	10.00%	10.00%
Preferred Stock, Conversion Period	Any time
Preferred Stock, Cumulative and undeclared dividends in arrears	$ 558,173

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash Flows from Operating Activities:
Net Income (loss)	$ (699)	$ 54
Adjustments to reconcile net income (loss) to cash (used in) provided by operations
Depreciation and amortization	170	202
Deferred taxes	80	(33)
Non-cash Interest	2	0
Changes in assets and liabilities:
Accounts receivable and allowance for doubtful accounts	(594)	(141)
Inventories	146	(557)
Prepaid expenses and other current assets	114	177
Accounts payable and accrued liabilities	(110)	(106)
Net cash (used in) provided by operating activities	(891)	(404)
Cash Flows from Investing activity:
Purchase of Equipment	(463)	(95)
Cash Acquired in Merger	1	0
Net cash provided from (used in) investing activities	(462)	(95)
Cash Flows from Financing activities:
Advances net of repayments on lines of credit	40	644
Proceeds from Sale of Common Stock	1,979	0
Term note repayments	(202)	(210)
Repayment of related party advance	(10)
Equity raise costs	(103)	0
Net cash provided by (used by) financing activities	1,704	434
Effect of exchange rates on cash and cash equivalents	(196)	75
Net increase in cash and cash equivalents	155	10
Cash and cash equivalents at beginning of year	75	65
Cash and cash equivalents at end of the period	230	75
Supplemental disclosure of cash flow information:
Cash paid for interest	276	314
Cash paid for income taxes	$ 124	$ 0

XML

Subsequent Event - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended
	Feb. 23, 2015	Mar. 31, 2015
Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues		240,625
Shares Issued, Price Per Share		$ 1.60
Stock Issued During Period, Value, New Issues		$ 385,000
Repayments of Debt	38,281
Agreed To Convert Of Preferred Stock For Common Stock	1,750,000
Dividends Payable, Current	656,250
Number Of Stock To Be Converted From Preferred Stock	12,000
Litigation Settlement, Amount	$ 15,000

XML

Reverse Merger - Additional Information (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended	0 Months Ended
	Dec. 31, 2014	Apr. 04, 2014	Apr. 03, 2014
Business Acquisition [Line Items]
Value of shares issued on acquisitions	$ 5,064
Medite Enterprises, inc [Member]
Business Acquisition [Line Items]
Proceeds from private placement	1,500	1,529
Number of shares issued on acquisitions		14,687,500
Number of shares issued		955,875
Percentage of ownership interests acquired		100.00%
Reverse Acquisition Percentage Of Share Issued	81.10%
Business Combination Consideration Outstanding Shares		3,502,700
Business Combination Consideration Outstanding Shares Per Share		$ 1.60
In Process Research And Development Amortized Term		15 years
Medite Enterprises, inc [Member] | Accrued Payroll Settlement [Member]
Business Acquisition [Line Items]
Number of shares issued on acquisitions			697,234
Value of shares issued on acquisitions			1,610
Number of additional shares issued on acquisitions		312,500
Minimum [Member] | Medite Enterprises, inc [Member]
Business Acquisition [Line Items]
Proceeds from private placement	$ 2,000

XML

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Property Plant And Equipment Useful Life

Property and equipment are stated at cost, less accumulated depreciation and amortization. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets as follows:

Buildings	33 yrs
Machinery and equipment	3-10yrs
Office furniture and equipment	2-10 yrs
Vehicles	5 yrs
Computer equipment	3-5 yrs

XML

Inventories - (Summary of the Components of Inventories) (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Inventory [Line Items]
Raw materials	$ 1,229	$ 1,748
Work in progress	33	137
Finished Goods	2,153	2,068
Inventory, Net	$ 3,415	$ 3,953

XML

Inventories (Tables)

12 Months Ended

Dec. 31, 2014

Inventory Disclosure [Abstract]

Schedule of Inventory

The following is a summary of the components of inventories (in thousands):

	December 31,		December 31,
	2014		2013
Raw materials	$	1,229	$	1,748
Work in progress		33		137
Finished Goods		2,153		2,068
	$	3,415	$	3,953

XML

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $) In Thousands, except Share data	Total	Preferred Stock [Member]	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning Balance at Dec. 31, 2012	$ 2,401	$ 0	$ 15	$ 0	$ (15)	$ 2,283	$ 118
Beginning Balance (in shares) at Dec. 31, 2012		0	14,687,500	0
Other comprehensive income	169						169
Net Income (loss)	54					54
Ending Balance at Dec. 31, 2013	2,624	0	15	0	(15)	2,337	287
Beginning Balance (in shares) at Dec. 31, 2013		0	14,687,500	0
Merger	5,064	1,487	3	(327)	3,901	0	0
Merger (in shares)		373,335	3,502,706	(19,209)
Sale of common stock	1,979	0	1	0	1,978	0	0
Sale of common stock (in shares)		0	1,237,125	0
Issuance costs	(103)	0	0	0	(103)	0	0
Imputed interest	2	0	0	0	2	0	0
Other comprehensive income		0	0	0	0
Net Income (loss)	(699)	0	0	0	0	(699)	(436)
Ending Balance at Dec. 31, 2014	$ 8,431	$ 1,487	$ 19	$ (327)	$ 5,763	$ 1,638	$ (149)
Ending Balance (in shares) at Dec. 31, 2014		373,335	19,427,331	(19,209)

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Preferred stock, par value	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred stock, shares issued	373,355	373,355
Preferred stock, shares outstanding	373,355	373,355
Preferred Stock, Liquidation Preference, Value	$ 2,871
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	3,500,000,000	3,500,000,000
Common Stock, Shares, Issued	19,427,331	14,687,500
Common Stock Issuable	19,427,331	14,687,500
Common Stock, Shares, Outstanding	19,427,331	14,687,500

XML

Income Taxes

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Income Taxes

Note 10. Income Taxes

The provision for income taxes consists of the following for the years ended December 31 (in thousands).  

	2014		2013
Federal	$	129	$	19
State and local		—		—
Foreign		(25)		—
Total income tax expense	$	104	$	19

	2014		2013
Current		152		51
Deferred		(48)		(32)
Total Income Tax Expense		104		19

At December 31, 2013, Medite had a deferred tax asset on the books of its US subsidiary of approximately $129,000, mostly as a result of prior year net operating loss carryforwards. Upon the consummation of the merger, the Company determined that the deferred tax asset had to be allowed for due to the subsidiary now be consolidated with the former CytoCore for income tax reporting purposes in the United States. The effect was to increase current year income tax expense by $129,000.

For the years ended December 31, 2014 and 2013, the provision for income taxes differs from the expected tax provision computed by applying the U.S. federal statutory rate to income before taxes as a result of the following:

	2014			2013
Statutory U.S. federal rate		(35.0)	%		25.0	%
Permanent differences		—			—
Change in estimate of German tax rates		(10)	%		—
Application of valuation allowance to US deferred tax assets upon merger		18	%		—
Other		—			—
Valuation allowance		44.0	%		—	%
Provision for income tax expense(benefit)		17	%		25	%

The significant components of the Company’s deferred tax assets and liabilities are as follows:

	2014		2013
	(in thousands)
Deferred Tax Assets:
Net Operating Loss Carryforwards	$	24,500		129
Accounts receivable timing differences		115		156
Property, plant and equipment		93
Total Deferred Tax Assets		24,708		285
Deferred Tax Liabilities:
Inventory Adjustment		-		(16)
Other		(39)		-
Total Deferred Tax Liabilities		(39)		(16)
Net Deferred Tax Asset		24,669		269
Valuation Allowance		(24,500)		-
Net Deferred Tax Asset	$	169		269

At December 31, 2014, the former CytoCore had net operating loss carry forwards for U.S. federal income tax of approximately $70 million, which will begin to expire in 2018.   In 2013 and 2014 the former CytoCore allowed its wholly owned subsidiaries to be administratively dissolved which resulted in the probable loss of their net operating loss carryforwards of approximately $3 million.  

For financial reporting purposes, the entire amount of deferred tax assets related principally to the net operating loss carry forwards has been offset by a valuation allowance due to uncertainty regarding the realization of the assets.

In 2013 and 2014 the former CytoCore had a change in ownership greater than 50%. The result of these changes is that the net operating loss carryforwards derived from US tax losses have become subject to the limitation requirements of Section 382 of the Internal Revenue Code in the United States. Section 382 requires that the Company obtain a special valuation that will allow it to calculate the yearly allowable percentage of its net operating loss carryforwards that will be usable in a given year over the next 20 years.

Tax Uncertainties

The Company follows the provisions of FASC 740-10 in accounting for uncertainty in income taxes. This guidance prescribes recognition and measurement parameters for the financial statement recognition and measurement of tax positions taken or expected to be taken in the Company’s tax return.   For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.   The amount recognized is measured as the largest amount of benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement.  

The Company has analyzed filing positions in all of the federal and state jurisdictions where it is required to file income tax returns, as well as open tax years in these jurisdictions. The periods subject to examination for the Company’s tax returns are for the years 2012, 2012 and 2013. The Company believes that its income tax filing positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded.

The following table summarizes the activity related to the Company’s gross unrecognized tax benefits (in thousands):

	Amount
Gross Unrecognized tax benefits at December 31, 2013	$	—
Increases in tax positions for current year		—
Settlements		—
Lapse in statute of limitations		—
Gross Unrecognized tax benefits at December 31, 2014	$	—

The Company is subject to U.S. federal income tax including state and local jurisdictions.   Currently, no federal or state income tax returns are under examination by the respective taxing jurisdictions.  

The Company’s accounting policy is to recognize interest and penalties related to uncertain tax positions in income tax expense.   The Company has not accrued interest for any periods.

XML

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	May 07, 2015	Jun. 30, 2014
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Registrant Name	Medite Cancer Diagnostics, Inc.
Entity Central Index Key	0000075439
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 9,145,062
Trading Symbol	MDIT
Entity Common Stock, Shares Outstanding		19,664,781

XML

Commitments and Contingencies

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and contingencies

Note 11. Commitments and contingencies

Legal Proceedings

Settled in 2014

None

Pending as of December 31, 2014

In 2014, we became subject to a lawsuit brought by D&D Technologies, Inc. (“D&D”) in the state of New Jersey for breach of contract and breach of implied covenant of good faith that occurred in 2013 and prior by the former CytoCore for failure to pay for past contractual services. The original complaint was dismissed and then refiled by D&D. D&D is seeking damages over $86,000 plus equitable relief. In 2015, the Company and D&D engaged in settlement negotiations and at the time of this filing had verbally agreed to settle the matter for approximately $15,000, however, no formal written settlement has yet been entered into.

CytoGlobe is subject to a court settlement on an alleged breach of the German competition law with Hologic Deutschland GmbH from August 2013. Both parties appealed the district court verdict at the higher regional court in September 2013, however at this time, the court has not schedule any further action and until such time as it does, the matter is at a standstill. As part of the decision from the local court, which the Company is appealing, the Company could be subject to a penalty up to a maximum of $304,000 if in the future it is found by the court to have improperly infringed on the product design of Hologic Deutchland GmbH.

Other Commitments

As a result of cash constraints experienced by the former CytoCore, the Illinois Franchise Taxes due for the year 2013, 2012, 2011, 2010 and 2009 have not been filed or paid. The Company believes that it has made adequate provision for the liability including penalties and interest. As the Company has moved its corporate headquarters out of the state of Illinois, it does not expect its liability going forward to increase substantially.

XML

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Net Sales	$ 10,983	$ 9,958
Operating Expenses
Cost of revenues	7,164	5,746
Depreciation and amortization expense	170	202
Research and development	1,243	934
Selling, general and administrative	2,800	2,782
Total cost and expenses	11,377	9,664
Operating Income (Loss)	(394)	294
Other Expenses
Interest expense	276	314
Interest Income	0	(48)
Other expenses (income)	(75)	(45)
Total other expenses	201	221
Income (loss) from operations before income taxes	(595)	73
Income taxes (benefit)	104	19
Net Income (loss)	(699)	54
Preferred dividend	(109)	0
Net Income (loss) to common stockholders	(808)	54
Statement of Comprehensive Income
Net Income (loss)	(699)	54
Other Comprehensive income (loss)
Foreign currency translation adjustments	(436)	168
Comprehensive income (loss)	(1,135)	222
Earnings Per Share
Net income (loss) to common stockholders	$ (808)	$ 54
Basic and diluted earnings per share	$ (0.04)	$ 0.00
Weighted average basic and diluted shares outstanding (after 1:100 reverse split)	18,116,000	14,687,500

XML

Property and Equipment

12 Months Ended

Dec. 31, 2014

Property, Plant and Equipment [Abstract]

Property and Equipment

Note 5. Property and Equipment

The following is a summary of the components of property and equipment as of (in thousands):

	December 31,		December 31,
	2014		2013
Land	$	233	$	244
Buildings		1,291		1,352
Machinery and equipment		529		407
Office furniture and equipment		265		240
Vehicles		103		39
Computer equipment		110		86
Construction in progress		559		386
Less: Accumulated depreciation		(999)		(887)
	$	2,091	$	1,867

XML

Inventories

12 Months Ended

Dec. 31, 2014

Inventory Disclosure [Abstract]

Inventories

Note 4. Inventories

The following is a summary of the components of inventories (in thousands):

	December 31,		December 31,
	2014		2013
Raw materials	$	1,229	$	1,748
Work in progress		33		137
Finished Goods		2,153		2,068
	$	3,415	$	3,953

No amounts were reserved for scrap or obsolete inventory as of December 31, 2014 and December 31, 2013, respectively.

XML

Reverse Merger (Tables)

12 Months Ended

Dec. 31, 2014

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

In connection with the merger, the consideration paid, and the assets acquired and liabilities assumed, recorded at fair value on the date of acquisition, are summarized in the following table:

	In thousands
Net assets acquired
Cash	$	1
Other current assets		12
Property and equipment		81
Trade name /trademark		1,240
In-Process research and development		4,620
Goodwill		2,453
	$	8,407
Liabilities assumed
Accounts payable & accrued expenses	$	3,220
Related party advances		102
Loans payable		21
	$	3,343
Net identifiable assets/consideration paid	$	5,064

XML

Segment Information

12 Months Ended

Dec. 31, 2014

Segment Reporting [Abstract]

Segment Information

Note 12. Segment Information

The Company operates in one operating segment. However, the Company has assets and operations in the United States and Germany. The following table shows the breakdown of our operations and assets by Country (in thousands):

	United States				Germany				Poland
	2014		2013		2014		2013		2014		2013
Total Assets	$	9,387	$	811	$	6,989	$	7,359	$	63	$	-
Property & equipment, net		98		17		1,985		1,850		8		-
Intangible Assets		8,315		2		58		63		4		-
Revenues		1,349		673		9,633		9,285		1		-
Net income (loss)		(730)		(20)		76		74		(45)		-

XML

Stockholders' Equity

12 Months Ended

Dec. 31, 2014

Equity [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Note 8. Stockholders’ Equity

In February 2015, the Company received approval for and affected a 1:100 reverse split of its common stock. These financial statements reflect the reverse split since inception of the Company.

 Earnings (loss) per share

A reconciliation of the numerator and the denominator used in the calculation of earnings (loss) per share is as follows:

	For the Years Ended December 31,
	2014		2013
Basic and Diluted:
Reported net loss (in thousands)	$	(699)	$	54
Less unpaid and undeclared preferred stock dividends		(109)		-
Net loss applicable to common stockholder	$	(808)	$	54
Weighted average common shares outstanding		18,116,000		14,687,500
Net income (loss) per common share	$	(0.04)	$	0.00

Because the following instruments would be anti-dilutive at all times presented, the potentially issuable common stock from warrants to purchase 142,308 and 39 shares in 2014 and 2013, respectively and preferred stock convertible into shares for the years ended December 31, 2014 and 2013, of 4,991 and 4,738 common shares respectively, were not included in the computation of diluted loss per share applicable to common stockholders.

Preferred Stock

A summary of the Company’s preferred stock as of December 31 is as follows. All calculations reflect the post-split calculations of 1 share for every 100 common shares which became effective March 2015 for all common stock and common stock equivalents.

			Shares Issued &				Preferred Stock Dividends
	Shares		Outstanding				Undeclared and Unpaid
Offering	Authorized		2014		2013		2014		2013
Series A convertible		590,197		47,250		47,250		—		—
Series B convertible, 10% cumulative		1,500,000		93,750		93,750		28,125		—
Series C convertible, 10% cumulative		1,666,666		38,333		38,333		8,625		—
Series D convertible, 10% cumulative		300,000		175,000		175,000		41,250		—
Series E convertible, 10% cumulative		800,000		19,022		19,022		31,500		—
Undesignated Preferred Series		5,143,137		—		—		—		—
Total Preferred Stock		10,000,000		373,355		373,355		109,500		—

The undeclared and unpaid preferred stock dividends were calculated from the date of the merger through December 31, 2014.

Summary of Preferred Stock Terms

Series A Convertible Preferred Stock

Liquidation Value:	$4.50 per share, $212,625
Conversion Price:	$10,303 per share
Conversion Rate:	0.00044—Liquidation Value divided by Conversion Price ($4.50/$10,303)
Voting Rights:	None
Dividends:	None
Conversion Period:	Any time

Series B Convertible Preferred Stock

Liquidation Value:	$4.00 per share, $375,000
Conversion Price:	$1,000 per share
Conversion Rate:	0.0040—Liquidation Value divided by Conversion Price ($4.00/$1,000)
Voting Rights:	None
Dividends:	10%—Quarterly—Commencing March 31, 2001
Conversion Period:	Any time

Cumulative dividends in arrears at December 31, 2014 were $520,665

Series C Convertible Preferred Stock

Liquidation Value:	$3.00 per share, $115,000
Conversion Price:	$600 per share
Conversion Rate:	0.0050—Liquidation Value divided by Conversion Price ($3.00/$600)
Voting Rights:	None
Dividends:	10%—Quarterly—Commencing March 31, 2002
Conversion Period:	Any time

Cumulative dividends in arrears at December 31, 2014 were $151,413

Series D Convertible Preferred Stock 

Liquidation Value:	$1,000 per share, $ 525,000
Conversion Price:	$1,000 per share
Conversion Rate:	.01—Liquidation Value divided by Conversion Price ($10.00/$1,000)
Voting Rights:	None
Dividends:	10%—Quarterly—Commencing April 30, 2002
Conversion Period:	Any time

Cumulative dividends in arrears at December 31, 2014 were $ 660,000

Series E Convertible Preferred Stock

Liquidation Value:	$22.00 per share, $418,488
Conversion Price:	$800.00 per share
Conversion Rate:	.0275—Liquidation Value divided by Conversion Price ($22.00/$800)
Voting Rights:	Equal in all respects to holders of common shares
Dividends:	10%—Quarterly—Commencing May 31, 2002
Conversion Period:	Any time

Cumulative dividends in arrears at December 31, 2014 were $558,173

Issuance of Securities

Common Stock  

Issuance of Common Stock for Cash

During 2014, the company issued 1,237,125 shares for $1,979,400 in equity proceeds emanating from the sale of unregistered stock associated with two private placements (PIPE) “Private Placement in Public Entity” at $1.60 per share.

Our officers and directors own an aggregate 16,661,615 shares of common stock which is approximately 86 % of our outstanding common stock.  

The Company does not have any outstanding stock options.

Warrants outstanding

							Weighted
			Weighted				Average
			Average		Aggregate		Remaining
	Options and		Exercise		Intrinsic		Contractual
	Warrants		Price		Value		Life (Years)
Outstanding at December 31, 2012		—	$	—		—		—
Granted		—	$	—		—		—
Exercised		—		—		—		—
Expired		—		—		—		—
Outstanding at December 31, 2013		—	$	—		—		—
Outstanding as result of the merger		62,140		4.00		—		9.00
Granted		81,298		1.60		—		4.50
Expired		(130)		4.00		—		—
Outstanding at December 31. 2014		143,308	$	2.64		—		6.46

XML

Bank Debt and Lines of Credit

12 Months Ended

Dec. 31, 2014

Debt Disclosure [Abstract]

Debt and Line of Credit

Note 6. Bank Debts and Lines of Credit

Our outstanding note payable indebtedness was as follows as of (in thousands):

	December 31,		December 31,
	2014		2013
Hannoversche Volksbank credit line #1	$	1,880	$	2,092
Hannoversche Volksbank credit line #2		465		444
Hannoversche Volksbank term loan #1		135		211
Hannoversche Volksbank term loan #2		81		138
Hannoversche Volksbank term loan #3		270		393
Ventana Medical Systems, Inc. Promissory Note		21		-
Related party advances		110		-
DZ Equity Partners Participation rights		912		1,032
	$	3,874	$	4,310

In July 2006, MEDITE GmbH, Burgdorf, entered into a master line of credit agreement #1 with Hannoversche Volksbank. The line of credit was amended in 2012 and was later amended to increase the credit limit to 1.8 million Euros. In January 2015, the master credit line was reduced to Euro 1.6 million and in March 2015 was to be reduced by a further Euro 500,000. The March 2015 reduction has been extended to May 31, 2015. The total credit line has a flexible use either as floating credit line with a variable interest rate of 8% per annum as of December 31, 2014, as “Eurocredit” fixed for one or more months with a short term fixed interest rate of 3.77% as of December 31, 2014 or as bank guarantee and for letters of credit in import business. The line of credit is collateralized by the accounts receivable and inventory of MEDITE GmbH, Burgdorf, a mortgage on the buildings owned by the Company and is guaranteed by Michaela Ott and Michael Ott, the former sole shareholders of the Company. At December 31, 2014 the Company had an unused and fully available credit line of Euro 150,000 with Hannoversche Volksbank.

In June 2012, CytoGlobe, GmbH, Burgdorf, entered into a line of credit agreement #2 with Hannoversche Volksbank. The line of credit granted a maximum borrowing authority of 400,000 Euros. The total credit line has a flexible use either as floating credit line with a variable interest rate of 8% per annum as of December 31, 2014, as “Eurocredit” fixed for one or more months with a short term fixed interest rate of 3.77% as of December 31, 2014 or as bank guarantee and for letters of credit in import business. The line of credit has no stated maturity date but may be cancelled by the bank upon notice to the Company. The line of credit is collateralized by the accounts receivable and inventory of CytoGlobe GmbH, Burgdorf and is guaranteed by Michaela Ott and Michael Ott, the former sole shareholders of the parent company and the state of Lower Saxony to support high-tech companies in the area.

In December 2006, MEDITE GmbH, Burgdorf, entered into a 500,000 Euro term loan agreement #1 with Hannoversche Volksbank with an interest rate of 3.4% per annum. The term loan has a maturity of September 2016 and requires semi-annual principal payments of approximately 27,780 euros each. The term loan is guaranteed by Michaela Ott and Michael Ott, the former sole stockholders of the Company and also a mortgage on the property of the Company.

In June 2006, MEDITE GmbH, Burgdorf, entered into a 400,000 Euro term loan #2 with Hannoversche Volksbank with an interest rate of 3.6 % per annum. The term loan has a maturity of June 2016, requires 18 semi-annual principal repayments of approximately 22,220 Euro each. The term loan is guaranteed by Michaela Ott and Michael Ott, the former sole stockholders of the Company and also has subordinated assignments of all of the receivables and inventories of MEDITE GmbH, Burgdorf and also has a subordinated pledge of stockholder term life insurance policies.

In November 2008, MEDITE GmbH, Burgdorf, entered into a 400,000 euro term loan #3 with Hannoversche Volksbank with a variable interest rate of approximately 4.7% per annum as of December 31, 2014. The term loan has a maturity of December 31, 2018, and requires quarterly principal repayments of 13,890 euro each. The term loan is guaranteed by the Ott’s and also includes a partial subordinated pledge of the receivables and inventory of MEDITE GmbH, Burgdorf.

In March 2009, the Company entered into a participation rights agreement in the form of a debenture which a mezzanine lender agreed to advance the Company up to 1.5 million euros in two tranches of 750,000 euros each. The first tranche was paid to the Company at closing with the second tranche being conditioned on MEDITE GmbH, Burgdorf and its subsidiaries hitting certain performance targets. Those targets were not met and the second tranche was never called. The debenture pays interest at the rate of 12.15% per annum and matures at December 31, 2016.

As of December 31, 2014 the remaining balance of approximately $21,000 on the note payable to Ventana Medical Systems, Inc. was in default, however, on February 23, 2015, The Company reached an agreement with Ventana Medical Systems, Inc. whereby both parties have agreed that Ventana Medical Systems, Inc. accept $38,281 as payment in full for all outstanding principal and accrued interest. As part of this agreement Ventana Medical Systems, Inc. has agreed to convert $1.75 million stated value of Series D Preferred stock and all outstanding accrued dividends of $656,250 for 12,000 shares of the company common stock. Prior to the execution of this agreement the company had failed to make principal and interest payments when due and is in breach of certain warranties and representations under the notes included above.

At the time of the merger, the Company owed its then CEO and Chairman of the Board for prior advances of approximately $121,700. During 2014, the Company had re-paid $10,000 and imputed $1,700 of non-cash charge interest expenses on these advances.

The following table summarizes the maturities of the Company’s outstanding long-term indebtedness, at December 31, 2014 over the following five years (in thousands):

Year
2015	$	189
2016		1,074
2017		68
2018		67
2019		-
Total	$	1,398

XML

Accrued Expenses

12 Months Ended

Dec. 31, 2014

Payables and Accruals [Abstract]

Accrued Expenses

Note 7. Accrued Expenses

Accrued expenses include the following at December 31:

	2014		2013
	(in thousands)
Accrued taxes and withholdings	$	445		211
Accrued warranty reserve		46		98
Accrued wages		2,064		57
Other accrued expenses		623		120
Total	$	3,178	$	486

XML

Leases

12 Months Ended

Dec. 31, 2014

Leases [Abstract]

Leases

Note 9. Leases

The terms of our current facilities leases vary from 3 months’ notice for part of the German and 6 month notice for the Poland facility to a term agreement until June 30, 2015 for the laboratory facility in the Chicago area and until July 31, 2018 for the Orlando facility. The monthly rent for the Orlando facility will increase from currently $2,345 to $ 2,563 per month in the last year. The previous down town Chicago facility lease contract term is October 30, 2016 with a monthly lease of $4,270. This facility currently is subleased at $3,816 per month. Total rental expenses was $157,136 in 2014.  The following table is not reduced by the sub-lease income of the Chicago facility.

Future minimum annual lease obligations under these leases as of December 31, 2014 are:

	Operating
Year	Leases
	(in thousands)
2015	$	112
2016		72
2017		33
2018		18
2019
Total	$	235

XML

Reverse Merger - (Estimated Purchase Price Allocation) (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Net assets acquired
Cash	$ 1
Other current assets	12
Property and equipment	81
Trade name /trademark	1,240
In-Process research and development	4,620
Goodwill	2,453	0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets	8,407
Liabilities assumed
Accounts payable & accrued expenses	3,220
Related party advances	102
Loans payable	21
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	3,343
Net identifiable assets/consideration paid	$ 5,064

XML

Income Taxes (Provision For Federal Income Taxes) (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Federal	$ 129	$ 19
State and local	0	0
Foreign	(25)	0
Total income tax expense	$ 104	$ 19

XML

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Principle of Consolidation, Basis of Presentation and Significant Estimates

 Principle of Consolidation, Basis of Presentation and Significant Estimates

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.

In preparing the accompanying financial statements, management has made certain estimates and assumptions that affect reported amounts in the financial statements and disclosures of contingencies. Significant assumptions are required in the valuation of the allowance for doubtful accounts and inventory, valuation of intangible assets acquired in the reverse merger and deferred tax asset valuations. Changes in facts and circumstances may result in revised estimates and actual results may differ from these estimates.

Revenue Recognition

Revenue Recognition  

The Company derives its revenue primarily from the sale of medical products and supplies for the diagnosis and prevention of cancer. Product revenue is recognized when all four of the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products has occurred; (3) the selling price of the product is fixed or determinable; and (4) collectability is reasonably assured. The Company generates the majority of its revenue from the sale of inventory. The Company recognizes revenue when title and risk of loss transfer to the customer and all other revenue recognition criteria have been met. For a small subset of sales, the Company and its customers agree in the sales contract that risk of loss and title transfer upon the Company packing the items for shipment, segregating the items packaged and notifying the Customer that their items are ready for pickup. The Company records such sales at time of completed packaging and segregation of the items from general inventory and notification has been confirmed by the customer.

Cash and Cash Equivalents

Cash and Cash Equivalents

 The Company considers all cash on deposit and highly-liquid debt instruments purchased with original maturities of three months or less to be cash and cash equivalents.

Property and Equipment

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation and amortization. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets as follows:

Buildings	33 yrs
Machinery and equipment	3-10yrs
Office furniture and equipment	2-10 yrs
Vehicles	5 yrs
Computer equipment	3-5 yrs

Normal maintenance and repairs for equipment are charged to expense as incurred, while significant improvements are capitalized.

Research and Development

Research and Development

All research and development costs are expensed as incurred. Research and development costs consist of engineering, product development, testing, developing and validating the manufacturing process, and regulatory related costs.

Acquired In-Process Research and Development

Acquired In-Process Research and Development

Acquired in-process research and development (“IPR&D”) that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, Medite will make a determination as to the then useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company tests IPR&D for impairment at least annually, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the IPR&D intangible asset is less than its carrying amount. If the Company concludes it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the IPR&D intangible asset with its carrying value is performed. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.

Impairment or Disposal of Long-Lived Assets Including Finite Lived Intangibles

Impairment or Disposal of Long-Lived Assets Including Finite Lived Intangibles

At each balance sheet date or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, management of the Company evaluates the recoverability of such assets. An impairment loss is recognized if the amount of undiscounted cash flows is less than the carrying amount of the asset, in which case the asset is written down to fair value. The fair value of the asset is measured by either quoted market prices or the present value of estimated expected future cash flows using a discount rate commensurate with the risks involved. Unless events or circumstances have changed significantly, we generally do not re-test at year end assets acquired from a business combination in the year of acquisition.

Impairment of Indefinite Lived Intangible Assets Other Than Goodwill

Impairment of Indefinite Lived Intangible Assets Other Than Goodwill

The Company has the option first to assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, the Company concludes that it is not more likely than not that the indefinite-lived intangible asset is impaired, then the entity is not required to take further action. However, if the Company concludes otherwise, then it is required to determine the fair value of the indefinite-lived intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying amount in accordance with Financial Accounting Standards Board Codification Subtopic 350-30.

Goodwill

Goodwill

We allocate goodwill to reporting units based on the reporting unit expected to benefit from the business combination. We evaluate our reporting units on an annual basis. Goodwill is tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis (December 31 for us) and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit. Unless events or circumstances have changed significantly, we generally do not re-test at year end assets acquired from a business combination in the year of acquisition.

Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The fair value of each reporting unit is estimated using a discounted cash flow methodology. This analysis requires significant judgments, including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for our business, estimation of the useful life over which cash flows will occur, and determination of our weighted average cost of capital.

The estimates used to calculate the fair value of a reporting unit change from year to year based on operating results, market conditions, and other factors. Changes in these estimates and assumptions could materially affect the determination of fair value and goodwill impairment for each reporting unit.

Stock Based Compensation

Stock Based Compensation

We follow the guidance of FASB ASC 718-10, which requires that share-based payments be reflected as an expense based upon the grant-date fair value of those awards.   The expense is recognized over the remaining vesting periods of the awards, if any.  

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The carrying value of accounts receivable, accounts payable, accrued expenses and notes payable approximate their respective fair values due to their short maturities.

Net Loss Per Share

Net Loss Per Share

Basic loss per share is calculated based on the weighted-average number of outstanding common shares. Diluted loss per share is calculated based on the weighted-average number of outstanding common shares plus the effect of dilutive potential common shares, using the treasury stock method. MEDITE’s calculation of diluted net loss per share excludes potential common shares as of December 31, 2014 and 2013 as the effect would be anti-dilutive (i.e. would reduce the loss per share).

 In accordance with SEC Accounting Series Release 280, the Company computes its income or loss applicable to common stock holders by subtracting dividends on preferred stock, including undeclared or unpaid dividends if cumulative, from it reported net loss and reports the same on the face of its statement of operations.

Income Taxes

Income Taxes  

Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of currently due plus deferred taxes. Deferred tax assets and liabilities are determined based on differences between financial reporting carrying amounts and the respective tax bases of assets and liabilities, and are measured using tax rates and laws that are expected to be in effect when the differences are expected to be recovered or settled. Valuation allowances are provided against deferred tax assets if it is more likely than not that the deferred tax assets will not be realized.

The Company follows the guidance of FASB ASC 740-10 which relates to the Accounting for Uncertainty in Income Taxes, which seeks to reduce the diversity in practice associated with the accounting and reporting for uncertainty in income tax positions. This Interpretation prescribes a comprehensive model for financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns.

Legal Fees Associated with Loss Contingencies

Legal Fees Associated with Loss Contingencies

It is the Company’s policy to estimate and accrue for its potential legal fees at the time of loss when it incurs a loss contingency that will require the services of legal professionals. Changes over time to the estimate of total legal fees to be incurred are expensed at the time of the change in estimate.

Recasting of Certain Prior Period Information

Recasting of Certain Prior Period Information

During 2014, we changed our reporting to show depreciation and amortization as its own line item within our statement of operations and comprehensive income. We have updated the results from 2013 to reflect these changes in 2014.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board issued amended accounting guidance on revenue recognition that will be applied to all contracts with customers. The objective of the new guidance is to improve comparability of revenue recognition practices across entities and to provide more useful information to users of financial statements through improved disclosure requirements. This guidance is effective for annual and interim periods beginning in 2017. Early adoption is not permitted. The Company is currently assessing the impact of adoption on its consolidated financial statements.

XML

Bank Debts and Line of Credit (Tables)

12 Months Ended

Dec. 31, 2014

Debt Disclosure [Abstract]

Outstanding note payable indebtedness

Our outstanding note payable indebtedness was as follows as of (in thousands):

	December 31,		December 31,
	2014		2013
Hannoversche Volksbank credit line #1	$	1,880	$	2,092
Hannoversche Volksbank credit line #2		465		444
Hannoversche Volksbank term loan #1		135		211
Hannoversche Volksbank term loan #2		81		138
Hannoversche Volksbank term loan #3		270		393
Ventana Medical Systems, Inc. Promissory Note		21		-
Related party advances		110		-
DZ Equity Partners Participation rights		912		1,032
	$	3,874	$	4,310

Schedule of Maturities of Long-term Debt

The following table summarizes the maturities of the Company’s outstanding long-term indebtedness, at December 31, 2014 over the following five years (in thousands):

Year
2015	$	189
2016		1,074
2017		68
2018		67
2019		-
Total	$	1,398

XML

Leases (Future Minimum Annual Lease Payments Under These Leases) (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014
2015	$ 112
2016	72
2017	33
2018	18
2019
Total	$ 235

XML

Accrued Expenses (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Accrued taxes and withholdings	$ 445	$ 211
Accrued warranty reserve	46	98
Accrued wages	2,064	57
Other accrued expenses	623	120
Total	$ 3,178	$ 486

XML

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Parenthetical)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Stockholders' Equity, Reverse Stock Split	1:100	1:100

XML

Reverse Merger

12 Months Ended

Dec. 31, 2014

Business Combinations [Abstract]

Reverse Merger

Note 3. Reverse merger

In January 2014, the Company and the owners of MEDITE Enterprise, Inc. entered into an agreement to merge with the former CytoCore, Inc. The merger required as a pre-requisite that among other items CytoCore settle certain outstanding payroll amounts in stock and that CytoCore complete a private placement with gross proceeds of a minimum of $2 million, which was later amended to $1.5 million. On April 3, 2014 CytoCore issued 697,234 shares of its common stock in satisfaction of approximately $1.61 million in outstanding accrued payroll. On April 4, 2014 the Company closed on a private placement in which it received gross proceeds of $1.529 million and issued 955,875 shares of its common stock. The merger closed on April 4, 2014 with the owners of MEDITE Enterprise, Inc. receiving 14,687,500 shares of the Company’s common stock plus up to an additional 312,500 shares issuable if certain conditions are met, in exchange for 100% of the issued and outstanding stock of MEDITE Enterprise, Inc.

As of the date of these financial statements, the Company has not yet determined if the additional shares should be issued. The consideration paid has been determined based the number of shares outstanding from the former CytoCore, Inc. of approximately 3,502,700 common shares at $1.60 per share (the same price per share in the concurrent private placement noted above).

Because the owners of MEDITE Enterprise, Inc. received approximately 81.1% of the then issued and outstanding stock of the Company, the merger has been treated as a reverse acquisition, in which for accounting purposes MEDITE Enterprise, Inc. acquired CytoCore, Inc. and therefore no pro forma information has been presented.

Under the purchase method of accounting, the Company assets acquired and liabilities assumed are recorded at their respective fair values as of the transaction date. In connection with the merger, the consideration paid, and the assets acquired and liabilities assumed, recorded at fair value on the date of acquisition, are summarized in the following table:

	In thousands
Net assets acquired
Cash	$	1
Other current assets		12
Property and equipment		81
Trade name /trademark		1,240
In-Process research and development		4,620
Goodwill		2,453
	$	8,407
Liabilities assumed
Accounts payable & accrued expenses	$	3,220
Related party advances		102
Loans payable		21
	$	3,343
Net identifiable assets/consideration paid	$	5,064

We are treating the fair value assigned to trade names/trademarks as indefinite lived intangibles. The in process research and development covers four separate areas (a) breast pap device and related consumables (b) new biomarkers (c) a new stain and (d) the softkit. Until such time as we either complete development or abandon such development, the in-process research and development costs are treated as indefinite lived intangible assets. If we are successful in these development projects, we expect the in-process research and development will be amortized over an approximate 15 year life.

XML

Segment Information (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Total Assets	$ 16,439	$ 8,170
Property & equipment, net	2,091	1,867
Net income (loss)	(699)	54
United States [Member]
Segment Reporting Information [Line Items]
Total Assets	9,387	811
Property & equipment, net	98	17
Intangible Assets	8,315	2
Revenues	1,349	673
Net income (loss)	(730)	(20)
Germany [Member]
Segment Reporting Information [Line Items]
Total Assets	6,989	7,359
Property & equipment, net	1,985	1,850
Intangible Assets	58	63
Revenues	9,633	9,285
Net income (loss)	76	74
Poland [Member]
Segment Reporting Information [Line Items]
Total Assets	63	0
Property & equipment, net	8	0
Intangible Assets	4	0
Revenues	1	0
Net income (loss)	$ (45)	$ 0

XML

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2014

Payables and Accruals [Abstract]

Accrued Expenses

Accrued expenses include the following at December 31:

	2014		2013
	(in thousands)
Accrued taxes and withholdings	$	445		211
Accrued warranty reserve		46		98
Accrued wages		2,064		57
Other accrued expenses		623		120
Total	$	3,178	$	486

XML

Bank Debts and Lines of Credit (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Line of Credit Facility [Line Items]
Long-term Debt, Gross	$ 3,874	$ 4,310
Hannoversech Volksbank Credit line 1 [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Gross	1,880	2,092
Hannoversech Volksbank Credit line 2 [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Gross	465	444
Hannoversech Volksbank term loan 1 [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Gross	135	211
Hannoversech Volksbank term loan 2 [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Gross	81	138
Hannoversech Volksbank term loan 3 [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Gross	270	393
Ventana Medical Systems, Inc. Promissory Note [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Gross	21	0
Related party advances [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Gross	110	0
DZ Equity Partners Participation rights [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Gross	$ 912	$ 1,032

XML

Subsequent Event

12 Months Ended

Dec. 31, 2014

Subsequent Events [Abstract]

Subsequent Event

Note 13. Subsequent Event

During 2015, the company issued 240,625 shares of unregistered stock to qualified individuals under SEC Rule 144 at $1.60 for proceeds of $385,000.

On February 23, 2015, The Company reached an agreement with Ventana Medical Systems, Inc. whereby both parties have agreed that Ventana Medical Systems, Inc. accept $38,281 as payment in full for all outstanding principal and accrued interest. As part of this agreement Ventana Medical Systems, Inc. has agreed to convert $1.75 million stated value of Series D Preferred stock and all outstanding accrued dividends of $656,250 for 12,000 shares of the company common stock.

To date the Company has reached a verbal settlement regarding outstanding litigation with D&D Technology which calls for a final payment of $15,000 by MEDITE to D&D Technology, the written settlement is pending. All expected liabilities are accrued in our financial statement.